Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: sylvester80 who wrote (1351685)	3/31/2022 2:32:15 PM
From: Jack Be Quick	1 Recommendation Recommended By Broken_Clock Respond to of 1578660

Yes, it does appear to be an actual report of a study, which can be read here: nejm.org Below is an excerpt from the description of the study. I am not a Biologist, but it looks to me like the study purposely included patients who were older, sicker, and Vaxxed. Is that the entire universe of people who might benefit from a Covid-19 treatment? Does that give this study general applicability? Should we continue to ban even the mention of Ivermectin as a treatment - except, of course, in the NEJM? Excerpt: PATIENTS On presentation to one of the trial outpatient care clinics, potential participants were screened to identify those meeting the eligibility criteria. Inclusion criteria were an age of 18 years or older; presentation to an outpatient care setting with an acute clinical condition consistent with Covid-19 within 7 days after symptom onset; and at least one high-risk criterion for progression of Covid-19, including an age of 50 years or older, diabetes mellitus, hypertension leading to the use of medication, cardiovascular disease, lung disease, smoking, obesity (defined as a body-mass index [the weight in kilograms divided by the square of the height in meters] of >30), organ transplantation, chronic kidney disease (stage IV) or receipt of dialysis, immunosuppressive therapy (receipt of =10 mg of prednisone or equivalent daily), a diagnosis of cancer within the previous 6 months, or receipt of chemotherapy for cancer. Patients who had been vaccinated against SARS-CoV-2 were eligible for participation in the trial. Further inclusion and exclusion criteria are listed in the trial protocol. 10